Literature DB >> 19399879

Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment.

Judy Pa1, Adam Boxer, Linda L Chao, Adam Gazzaley, Katie Freeman, Joel Kramer, Bruce L Miller, Michael W Weiner, John Neuhaus, Julene K Johnson.   

Abstract

OBJECTIVE: Subgroups of mild cognitive impairment (MCI) have been proposed, but few studies have investigated the nonamnestic, single-domain subgroup of MCI. The goal of the study was to compare clinical and neuroimaging characteristics of two single-domain MCI subgroups: amnestic MCI and dysexecutive MCI.
METHODS: We compared the cognitive, functional, behavioral, and brain imaging characteristics of patients with amnestic MCI (n = 26), patients with dysexecutive MCI (n = 32), and age- and education-matched control subjects (n = 36) using analysis of variance and chi(2) tests. We used voxel-based morphometry to examine group differences in brain magnetic resonance imaging atrophy patterns.
RESULTS: Patients with dysexecutive MCI had significantly lower scores on the majority of executive function tests, increased behavioral symptoms, and left prefrontal cortex atrophy on magnetic resonance imaging when compared with control subjects. In contrast, patients with amnestic MCI had significantly lower scores on tests of memory and a pattern of atrophy including bilateral hippocampi and entorhinal cortex, right inferior parietal cortex, and posterior cingulate gyrus when compared with control subjects.
INTERPRETATION: Overall, the clinical and neuroimaging findings provide support for two distinct single-domain subgroups of MCI, one involving executive function and the other involving memory. The brain imaging differences suggest that the two MCI subgroups have distinct patterns of brain atrophy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399879      PMCID: PMC2680500          DOI: 10.1002/ana.21591

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  42 in total

1.  The Dysexecutive Questionnaire advanced: item and test score characteristics, 4-factor solution, and severity classification.

Authors:  Sebastian Bodenburg; Nina Dopslaff
Journal:  J Nerv Ment Dis       Date:  2008-01       Impact factor: 2.254

2.  Mild cognitive impairment: long-term course of four clinical subtypes.

Authors:  A Busse; A Hensel; U Gühne; M C Angermeyer; S G Riedel-Heller
Journal:  Neurology       Date:  2006-12-26       Impact factor: 9.910

3.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment.

Authors:  J L Whitwell; M M Shiung; S A Przybelski; S D Weigand; D S Knopman; B F Boeve; R C Petersen; C R Jack
Journal:  Neurology       Date:  2007-09-26       Impact factor: 9.910

4.  Neuropsychiatric symptoms in amnestic and nonamnestic mild cognitive impairment.

Authors:  L Rozzini; B Vicini Chilovi; M Conti; I Delrio; B Borroni; M Trabucchi; A Padovani
Journal:  Dement Geriatr Cogn Disord       Date:  2007-11-19       Impact factor: 2.959

5.  Prevalence of subcortical vascular lesions and association with executive function in mild cognitive impairment subtypes.

Authors:  Stéphanie Bombois; Stéphanie Debette; Xavier Delbeuck; Amélie Bruandet; Samuel Lepoittevin; Christine Delmaire; Didier Leys; Florence Pasquier
Journal:  Stroke       Date:  2007-07-26       Impact factor: 7.914

6.  Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment.

Authors:  Anne Hämäläinen; Susanna Tervo; Marta Grau-Olivares; Eini Niskanen; Corina Pennanen; Jari Huuskonen; Miia Kivipelto; Tuomo Hänninen; Mia Tapiola; Matti Vanhanen; Merja Hallikainen; Eeva-Liisa Helkala; Aulikki Nissinen; Ritva Vanninen; Hilkka Soininen
Journal:  Neuroimage       Date:  2007-06-29       Impact factor: 6.556

7.  Magnetic resonance imaging correlates of set shifting.

Authors:  Joel H Kramer; Lovingly Quitania; David Dean; John Neuhaus; Howard J Rosen; Cathra Halabi; Michael W Weiner; Vincent A Magnotta; Dean C Delis; Bruce L Miller
Journal:  J Int Neuropsychol Soc       Date:  2007-05       Impact factor: 2.892

8.  Patterns of atrophy differ among specific subtypes of mild cognitive impairment.

Authors:  Jennifer L Whitwell; Ronald C Petersen; Selamawit Negash; Stephen D Weigand; Kejal Kantarci; Robert J Ivnik; David S Knopman; Bradley F Boeve; Glenn E Smith; Clifford R Jack
Journal:  Arch Neurol       Date:  2007-08

9.  D-KEFS Trail Making Test performance in patients with lateral prefrontal cortex lesions.

Authors:  Brian Yochim; Juliana Baldo; Adam Nelson; Dean C Delis
Journal:  J Int Neuropsychol Soc       Date:  2007-05-18       Impact factor: 2.892

Review 10.  Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature.

Authors:  Liana G Apostolova; Jeffrey L Cummings
Journal:  Dement Geriatr Cogn Disord       Date:  2007-12-14       Impact factor: 2.959

View more
  43 in total

1.  Gray matter correlates of set-shifting among neurodegenerative disease, mild cognitive impairment, and healthy older adults.

Authors:  Judy Pa; Katherine L Possin; Stephen M Wilson; Lovingly C Quitania; Joel H Kramer; Adam L Boxer; Michael W Weiner; Julene K Johnson
Journal:  J Int Neuropsychol Soc       Date:  2010-04-07       Impact factor: 2.892

Review 2.  Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Cutter A Lindbergh; Rodney K Dishman; L Stephen Miller
Journal:  Neuropsychol Rev       Date:  2016-07-08       Impact factor: 7.444

3.  Rule violation errors are associated with right lateral prefrontal cortex atrophy in neurodegenerative disease.

Authors:  Katherine L Possin; Simona M Brambati; Howard J Rosen; Julene K Johnson; Judy Pa; Michael W Weiner; Bruce L Miller; Joel H Kramer
Journal:  J Int Neuropsychol Soc       Date:  2009-05       Impact factor: 2.892

4.  Dysexecutive versus amnestic Alzheimer disease subgroups: analysis of demographic, genetic, and vascular factors.

Authors:  Jesse Mez; Stephanie Cosentino; Adam M Brickman; Edward D Huey; Jennifer J Manly; Richard Mayeux
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Jul-Sep       Impact factor: 2.703

5.  Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment.

Authors:  Carrie R McDonald; Lusineh Gharapetian; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Dominic Holland; Anders M Dale
Journal:  Neurobiol Aging       Date:  2010-05-14       Impact factor: 4.673

6.  APOE epsilon4 and the cognitive genetics of multiple sclerosis.

Authors:  O Ghaffar; M Reis; N Pennell; P O'Connor; A Feinstein
Journal:  Neurology       Date:  2010-05-18       Impact factor: 9.910

7.  Dysexecutive functioning in mild cognitive impairment: derailment in temporal gradients.

Authors:  Joel Eppig; Denene Wambach; Christine Nieves; Catherine C Price; Melissa Lamar; Lisa Delano-Wood; Tania Giovannetti; Brianne M Bettcher; Dana L Penney; Rod Swenson; Carol Lippa; Anahid Kabasakalian; Mark W Bondi; David J Libon
Journal:  J Int Neuropsychol Soc       Date:  2011-10-07       Impact factor: 2.892

Review 8.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.

Authors:  Chia-Chen Liu; Chia-Chan Liu; Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Nat Rev Neurol       Date:  2013-01-08       Impact factor: 42.937

9.  Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study.

Authors:  M Schuur; P Henneman; J C van Swieten; M C Zillikens; I de Koning; A C J W Janssens; J C M Witteman; Y S Aulchenko; R R Frants; B A Oostra; K Willems van Dijk; C M van Duijn
Journal:  Eur J Epidemiol       Date:  2010-06-29       Impact factor: 8.082

10.  Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease.

Authors:  Kwangsik Nho; Shannon L Risacher; Paul K Crane; Charles DeCarli; M Maria Glymour; Christian Habeck; Sungeun Kim; Grace J Lee; Elizabeth Mormino; Shubhabrata Mukherjee; Li Shen; John D West; Andrew J Saykin
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.